DUAVIVE, a new hormone replacement therapy (HRT) from MSD is now available for the management of menopausal symptoms in women for whom traditional progestogen-containing therapy is not appropriate.

The new treatment combines conjugated oestrogens (HRT) with bazedoxifene (BZA), a selective oestrogen receptor modulator. This combination is designed to alleviate menopausal symptoms at the same time as reducing the risk of endometrial cancer in women who have not had a hysterectomy.

About 20 per cent of women receiving HRT are unable to take progestogen, with about half this number having adverse events, such as weight gain, bloating, and migraine, shows research.

Dr John Stevenson, consultant physician and endocrinologist at the Royal Brompton Hospital, London, said: “The tissue-selective oestrogen complex concept represents a new paradigm in menopause management. For most women, any problems that arise from HRT result from the progestogen component, and this new HRT dispenses with progestogens.”